Compare Adaptive Biotechnologies Corp (ADPT) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs C.H. Robinson Worldwide, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while C.H. Robinson Worldwide, Inc. trades at $189.93 (market cap $22.49B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 6.8× Adaptive Biotechnologies Corp's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CHRW | |
|---|---|---|
Market Cap | $3.33B | $22.49B |
Sector | Health | Industrials |
52-Week High | $22.37 | $200.59 |
52-Week Low | $10.24 | $96.82 |
Enterprise Value | $3.19B | $23.98B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CH Robinson Worldwide (CHRW) trades at $190.95, up 0.58% with a bullish technical outlook. The stock shows strong profitability with ROE of 34.84% and has beaten earnings estimates for three consecutive quarters. Recent acquisitions like DeSpir Logistics and AI technology launches position the company for growth in logistics efficiency. Valuation metrics appear elevated with P/E of 38.18, though revenue has declined from 2022 peaks to $16.23B in 2025.
The outlook remains positive with analyst consensus target of $198.83 representing 4% upside. Key opportunities include AI-driven supply chain optimization and industry consolidation benefits, while risks involve freight market volatility and competitive pressures. Cash flow generation remains healthy with $915M operating cash flow in 2025 supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
